|
|
Volumn 35, Issue 4, 2008, Pages
|
|
Preface
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ALPHA2A INTERFERON;
BEVACIZUMAB;
CG 250 I 124;
HYPOXIA INDUCIBLE FACTOR 1ALPHA;
INTERLEUKIN 2;
IODINE 124;
IODINE DERIVATIVE;
PLACEBO;
PROTEIN TYROSINE KINASE INHIBITOR;
SORAFENIB;
SUNITINIB;
TEMSIROLIMUS;
UNCLASSIFIED DRUG;
VON HIPPEL LINDAU PROTEIN;
ADVANCED CANCER;
CANCER ADJUVANT THERAPY;
CANCER CHEMOTHERAPY;
CANCER GROWTH;
CANCER INCIDENCE;
CANCER MORTALITY;
CANCER REGRESSION;
CANCER SURGERY;
CANCER SURVIVAL;
CANCER THERAPY;
CLEAR CELL CARCINOMA;
CLINICAL TRIAL;
COMPUTER ASSISTED TOMOGRAPHY;
DRUG ERUPTION;
EDITORIAL;
ETHNICITY;
FATIGUE;
HAND FOOT SYNDROME;
HUMAN;
HYPERTENSION;
IMMUNOHISTOCHEMISTRY;
KIDNEY FUNCTION;
KIDNEY TUMOR;
NUCLEAR MAGNETIC RESONANCE IMAGING;
OBESITY;
PARTIAL NEPHRECTOMY;
PATHOGENESIS;
POSITRON EMISSION TOMOGRAPHY;
PRIORITY JOURNAL;
PROGNOSIS;
RISK FACTOR;
SURVIVAL TIME;
ULTRASOUND;
UNSPECIFIED SIDE EFFECT;
KIDNEY CORTEX;
MORTALITY;
NEPHRECTOMY;
PATHOLOGY;
SURVIVAL;
HUMANS;
KIDNEY CORTEX;
KIDNEY NEOPLASMS;
NEPHRECTOMY;
PROGNOSIS;
SURVIVAL ANALYSIS;
|
|
EID: 55049107703
PISSN: 00940143
EISSN: None
Source Type: Journal
DOI: 10.1016/j.ucl.2008.07.016 Document Type: Editorial |
|
Times cited : (10)
|
|
References (0)
|
